Federal Register of Legislation - Australian Government

Primary content

PB 61 of 2021 Other as made
This instrument amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015) to add, delete and alter listed pharmaceutical items and associated periods and circumstances.
Administered by: Health
Registered 29 Jun 2021
Tabling HistoryDate
Tabled HR03-Aug-2021
Tabled Senate03-Aug-2021
Date of repeal 19 Oct 2021
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 61 of 2021

 

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 6)

 

National Health Act 1953

___________________________________________________________________________

 

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated         29 June 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 6).

(2)          This Instrument may also be cited as PB 61 of 2021.

2          Commencement

This Instrument commences on 1 July 2021.

3          Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                             

                             


Schedule 1       Amendments

[1]        Schedule 1, entry for Captopril

omit:

 

Tablet 25 mg

20

90

5

 

 

Tablet 50 mg

20

90

5

 

[2]        Schedule 1, after entry for Indapamide in the form Tablet containing indapamide hemihydrate 2.5 mg

insert:

Infliximab

Solution for injection 120 mg in 1 mL pre-filled pen

20

1

0

 

 

 

20

2

0

 

 

 

20

2

2

 

 

 

20

2

5

 

 

Solution for injection 120 mg in 1 mL pre-filled syringe

20

1

0

 

 

 

20

2

0

 

 

 

20

2

2

 

 

 

20

2

5

 

[3]        Schedule 1, entry for Testosterone in the form Transdermal cream 50 mg per mL, 50 mL

omit from the column headed “Maximum number of repeats”: 6                         substitute: 1

[4]        Schedule 1, entry for Tofacitinib

substitute:

Tofacitinib

Tablet 5 mg

20

56

3

 

 

 

20

56

5

 

 

Tablet 10 mg

20

56

3

 

 

 

20

56

5